EURASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES
Innovative Academy Research Support Center
IF = 9.2
www.in-academy.uz/index.php/ejmns

THE INTERACTION OF MICROFLORA WITH THE HUMAN IMMUNE SYSTEM AND THE ANALYSIS OF MEASURES TO IMPROVE MICROFLORA

Fotima Sh. Mamatmusaeva[1]
Dilafruz Sh. Gulmurotova[2]
Durdona Sh. Safarova[3]
Ozoda S. Alimqulova[4].
[1]Associate Professor (PhD) at the Department of Microbiology, virology and immunology of Tashkent State Medical University, Tashkent, Uzbekistan, E-mail: mkomfo@mail.ru
[2]Assistant at the Department of Microbiology, virology and immunology of Tashkent State Medical University, Tashkent, Uzbekistan, E-mail: dilafruzgulmurotova82@gmail.com
[3]Student of Tashkent State Medical University, 2nd Faculty of General Medicine, Group 214A, Tashkent, Uzbekistan, E-mail: durdonasafarova2007@icloud.com
[4]Student of Tashkent State Medical University, 2nd Faculty of General Medicine, Group 214A, Tashkent, Uzbekistan, E-mail: ozodaalimqulova1308@gmail.com
https://doi.org/10.5281/zenodo.17588077

ARTICLE INFO

Received: 06th November 2025
Accepted: 11th November 2025
Online: 12th November 2025

KEYWORDS

Immunity, microbiota, molecular processes, biological processes, illnesses, novel treatment prospects.

ABSTRACT

The host immune system's induction, education, and operation are all significantly influenced by the microbiota. In exchange, the host immune system has developed a number of strategies for preserving its mutually beneficial association with the microbiota. Maintaining this conversation enables the use of regulatory mechanisms involved in the long-term tolerance to harmless antigens as well as the production of protective responses to pathogens. Tonic microbe detection and intricate feedback loops between the immune system's innate and adaptive components are necessary for microorganisms to be able to influence the immunological tone of tissues both locally and systemically. Here, we go over the main cellular mediators of these interactions and talk about new topics related to our present comprehension of the host-microbiota homeostatic immunological dialogue. Our health depends critically on the microbiome. It comprises several phyla, including Verrucomicrobia, Actinobacteria, Proteobacteria, Fusobacteria, Firmicutes and Bacteroidetes. There is a reciprocal relationship between immunity and microbiota interaction. The development of immunity is stimulated by the *microbiome. The makeup of microorganisms is influenced by immunity. Immune system regulation, pathogen invasion prevention, and homeostasis maintenance all depend on this interplay. Additionally, this mutually beneficial interaction is essential for preserving general health and averting a number of illnesses. The immune system enhances our immunity by selecting for healthy microbiota composition, while the microbiota–immune system aids in immune system maturation. This review provides strong evidence for the involvement of microbiota in immune control by summarizing the molecular processes and biological activities of the relationship between microbiota and immunity. Notably, the review describes illness correlations, molecular effectors, and functional results related to the microbiota–immune system while classifying bacteria according to phyla. Three fundamental basic mechanisms of the immune and microbial systems were also presented. We also describe how bacterial and immune-related illnesses progress from target discovery to therapeutic trial design. Lastly, we suggest four disease-treatment approaches.*

Introduction. Newer generations of medications must be continuously discovered. This process, which is driven by medical advancements and research on the corresponding disease entities, comes in response to the growing need for medications. Still, there are concerns over the effectiveness of medication in certain patient populations. Numerous factors, including age, sex, food, and genetic predisposition, affect how effective therapy is. The gut flora, which supports numerous bodily activities, must thus also be taken into consideration. All microorganisms in a given habitat, including bacteria, viruses, and eukaryota, are referred to as the microbiota. The gut is the densest and most varied habitat for microbes. There may be about 1000 different types of bacteria in the gut microbiota, each with its own metabolism and 150 times more genes than humans. A host's health state is linked to the strength of their gut microbiota; when commensals and pathogenic microbes are out of balance (a condition known as dysbiosis), patients may experience a range of symptoms or develop a specific disease [1,2,3,4]. The intricate relationships between medications and the microbiota are essential to the effectiveness of certain medications. Hydrolysis of linked or glycosidic substances is one of the most frequent xenobiotic reactions. The gut microbiota produces the enzymes beta-glucuronidase, beta-glucosidase, and sulfatase, which carry out this function. Acetylation, deconjugation, thiazole ring modification, denitration, and other processes occur in addition to hydrolytic reactions. By directly altering the host's metabolism and producing compounds that compete with receptors for pertinent medications, the gut microbiota can control the effects of treatment in addition to drug biotransformation. Metabolites of the microbiome can potentially control liver enzyme secretion and metabolism. In general, any alteration in the makeup of the gut microbiota may have an impact on the pharmacokinetics, pharmacodynamics, and toxicity of the medications that are broken down in the digestive tract. The acquisition of a complex microbiota has coincided with the development of distinct immune system arms, particularly those linked to adaptive immunity [5,6,7]. This suggests that a significant portion of the complex system evolved to preserve a symbiotic relationship with the microbiota. As a result, the immune system is essential for maintaining and forming the microbiota's ecology. The microbiota, in turn, supports and balances every component of the immune system, as this review discusses. In fact, commensals are essential for immune system training and functional tuning, thereby serving as adjuvants for the immune system overall. In addition to exhibiting higher ecological permissiveness, patients with primary immunodeficiencies frequently experience infections brought on by normal microbiota contents. Indeed, despite the fact that microbiota members are frequently referred to as commensals, the symbiosis (persistent interaction) between the microbiota and its mammalian host encompasses a variety of relationships, and the way that microbes interact with their host can vary greatly depending on the host's genetic makeup, nutritional status, or co-infection [8,9,10]. The human newborn is thrust into a world full of microorganisms as soon as they are born. During fetal development, the innate and adaptive immune systems evolve to defend against harmful microorganisms. In the postnatal period, microorganisms colonize the intestines and any other surface of the body that is exposed to the external environment. Commensal microorganisms are beneficial to human health and well-being and should not be targeted, but pathogenic microorganisms should be identified and eradicated by the immune system. This is what Philippe Sansonetti has called "war and peace on mucosal surfaces." The human immune system's development during the first 1000 days of life, when it further develops and diversifies, as well as its interactions with the microbiota, particularly those that live in the gastrointestinal (GI) tract, will be covered in this review. We'll talk about and contextualize the cellular and molecular specifics of these interactions [11,12,13,14].

The main purpose of the presented manuscript is a brief analysis of the interaction of microflora with the human immune system and measures to improve the microflora.

The connection between immunity and sleep, as well as how the gut microbiota affects sleep. It should go without saying that sleep is essential for good health. Lack of sleep is known to contribute to some illnesses. In fact, a lot of people use sleep to help them recover from illnesses. People started investigating the connection between sleep and health thousands of years ago. It has been suggested in recent decades that immunity and sleep are related. These days, relaxation and the immune system have a mutually reinforcing effect. It has been demonstrated that sleep controls inflammatory processes. An experiment that used several measures over a 24-hour period to assess circadian rhythms discovered that when poor sleep quality interferes with the normal circadian rhythm, growth is lowered by one-half when nocturnal sleep is completely denied, and the increase in IL-6 during sleep is encouraged. In a different experiment, the immune system demonstrated a dynamic shift during the typical sleep-wake cycle [1-5]. The quantity of immune cells peaked at night and then fell again in the morning. Furthermore, research has shown that sleep deprivation lowers immunity, which raises the risk of infectious diseases like influenza. In one experiment, volunteers received a known quantity of rhinoviruses as an inoculation, and for five to seven days, their sleep patterns were closely observed and controlled (figure 1).



Figure 1: The Mammalian Immune System's Induction, Education, and Function Are Fundamentally Influenced by the Microbiota [18].

The researchers discovered that the chance of getting a cold would rise if sleep duration and quality were reduced. Vaccination has emerged as the perfect experimental model to more clearly illustrate how sleep affects the immune response's durability. As an example, consider the immunological response that follows influenza vaccination. The subjects were split into two groups: those who slept for four hours each day and those who slept for eight hours. Both groups received influenza vaccinations. Ten days following vaccination, the concentration of influenza virus-specific antibody was twice as high in patients who slept eight hours a day as in subjects who slept four hours a day, according to the results [6-11]. Another experiment produced a similar outcome. Lack of sleep at night following H1N1 vaccination may decrease the antigen-specific antibody response. All of this evidence demonstrated how closely immunity and sleep are related. To boost immunity and, eventually, improve the quality of our sleep, we can take certain actions, such changing the way we eat or taking probiotics to intentionally control the makeup of our gut microbes [12,13,14].

The Microbiota's Tonic Regulation of Hematopoiesis and Innate Immunity. Bacterial metabolites are found in peripheral organs after commensal colonization, even though the host immune system and microbiota are anatomically separated, which restricts the systemic dispersal of commensal germs. It is yet unknown whether the systemic penetration of microbial metabolites is due to passive diffusion or active transport processes. Commensal metabolites and products that enter the bloodstream, however, have an effect on development and, as will be later described, the host immune system's ability to function. In fact, there is experimental evidence that steady-state hematopoiesis may be aided by the tonic detection of commensal products or metabolites in the bloodstream. Antibiotic therapy was demonstrated to decrease the granulocyte-macrophage colony formation frequency more than 30 years ago, and germ-free animals exhibit a widespread innate immune cell deficiency. Both the growth of myeloid cells generated from the yolk sac and stem cells can be influenced by the microbiota, and the complexity of the intestinal microbiota is correlated with the size of the bone marrow myeloid cell pool. CCR2-dependent monocyte emigration from the bone marrow is triggered by tonic sensing of trace amounts of LPS, a condition that may represent microbiota variation [11,12,14]. In response to circulating TLR ligands, bone marrow mesenchymal stem cells (MSCs) and their offspring can quickly produce MCP1, which facilitates monocyte trafficking into the bloodstream. When NOD1 ligands are administered in vivo to germ-free mice, the quantity of hematopoietic stem cells and precursors can also be brought back to the levels seen in particular pathogen-free animals. A ligand-dependent transcription factor, the aryl hydrocarbon receptor (AhR) detects endogenous and xenobiotic ligands, including those produced from the microbiota. Commensal bacteria's catabolism of food components containing tryptophan to indole derivatives is essential for maintaining AhR-mediated homeostasis at barrier surfaces. AhR-activation in the gastrointestinal tract encourages the production of IL-22 by T helper 17 (Th17) cells and group 3 innate lymphoid cells (ILC), as well as the preservation of intra-epithelial lymphocytes. Offspring of gestationally colonized mothers who consume commensal-catabolized indole derivatives have higher frequencies of mononuclear phagocytes and ILC3. Some of these effects are mediated by maternal antibodies, possibly through the retention of AhR-ligands to encourage transmission during pregnancy. The maintenance of intra-epithelial lymphocytes in the gut and the skin epidermis is facilitated by dietary-derived AhR-ligands, indicating the wide systemic distribution of these microbiota-conditioned compounds [15-21].

Modulation of the immune system. Together with the innate and adaptive immune systems, the gut microbiota also plays a role in gut immunomodulation. Gut associated lymphoid tissues (GALT), effector and regulatory T cells, IgA-producing B (plasma) cells, Group 3 innate lymphoid cells, resident macrophages, and dendritic cells in the lamina propria are among the immune system components and cell types that take part in the immunomodulatory process. The poor development of Peyer's patches and isolated lymphoid follicles, which are identified by the abundance of IgE+ B cells rather than the typically observed IgA+ B cells, suggest that gut microbiota plays a role in forming a proper GALT. It has also been demonstrated that Th2 responses, rather than

Th1 responses, are mostly responsible for regulating effector T cell responses in the intestine. The latter is mostly mediated by Th1 and Th17 cells in a physiological environment, and gut commensals are thought to activate IL1β through TLR-MyD88 signaling, which in turn encourages the generation of IL17 [4-9]. Additionally, the proper growth and operation of Foxp3+ T regulatory (Treg) cells depend on the intestinal microbiota. Nevertheless, it is still unclear how this is mediated. For instance, some Clostridium clusters may rely on mechanisms that are dependent on My-D88 may be independent of PRRs. TLR2 signaling by polysaccharide A appears to be the mechanism by which Bacillus fragilis induces Tregs. Treg formation and function have also been linked to SCFAs, particularly butyrate. SCFAs have been demonstrated to control Treg through epigenetic regulation (increased acetylation) of the Foxp3 locus and activate G-protein coupled receptors produced by the IECs. The steady-state expression of pro-IL1β by resident macrophages in the lamina propria has an immunomodulatory effect that facilitates the quick generation of mature IL1β in response to pathogen invasion [11-15]. This effect requires commensal flora-induced MyD-88 dependent processes, whereas the microbiota-regulated macrophage IL-10 production involves MyD-88 independent mechanisms. The gut immune system is modulated by a number of variables in addition to the gut flora. For instance, intestinal alkaline phosphatase, an isoform of alkaline phosphatase secreted by the IECs, dephosphorylates the LPS endotoxin. An additional illustration is the decreased recruitment of neutrophils into the intestinal lumen as a result of tumor necrosis factor-α (TNF-α). The intestinal alkaline phosphatase mediates this activity. Furthermore, the downregulation of IL-1 receptor-associated kinase (IRAK-1), which functions through TLR4, is an immunoprotective mechanism that is acquired at birth and is primarily observed with vaginal delivery [1,2,3].

Discussion. The human immune system begins to develop in a mainly, though perhaps not entirely, sterile environment during the prenatal stage. The immune system is exposed to a more complex microbiome during and after birth. The infant's gut is colonized by the first bacteria it encounters during birth canal transit, which causes the immune system to become tolerant. Breast milk's IgA and maternal IgG derived from transplacenta shield the baby from illnesses for the first 100 days, while the immune system continues to grow and immunological memory is established. Other microbiota can invade when the immune system is exposed to new (food) antigens during weaning and the introduction of solid food. We are now starting to identify the cells and chemicals that are involved in the complex and reciprocal interactions between the growing immune system and microbiota. These consist of bacterial constituents such Bacteroides fragilis polysaccharide A and bacterial metabolites like butyrate, indole-3-aldehyde, and indole-3-propionic acid, which are short-chain fatty acids. These and most likely other bacterial metabolites have distinct immunoregulatory roles that influence how the human immune system develops in the first 1000 days of life [1-7]. New generations of medications are discovered as science and pharmacology advance. This link, which is driven by medical advancements and research on the relevant substances, is a reaction to the rising need for medications. The effectiveness of medication in specific patient populations, however, raises concerns. Numerous factors, including age, sex, diet, and genetic predisposition, affect how effective a therapy is. As a result, we also need to focus on the microbiota, which performs numerous roles in the human body. It has been shown that medications used in psychiatry, gastroenterology, diabetes, and other medical specialties have a great deal of potential to alter the gut microbiota's composition and likely function, which raises the risk of chronic diseases in the long run. The sterile environment of the uterus is where human embryonic and fetal development occurs. As early as week 4 of pregnancy, the first lymphoid progenitor cells can be identified, and by week 20, every immune system component has actually developed. The newborn immune system is not exposed to microbial antigens until delivery due to the sterile environment of the uterus. The baby encounters a wide range of microorganisms, including possible diseases, as soon as it is introduced to the outside world. The neonatal immune system is stimulated by both microbial and non-microbial antigens throughout the first 1000 days of life. It will react to these stimuli and form immunological memory [8-13]. The immune system needs to be able to distinguish between "self" and "non-self" in order to produce a particular response to microbial antigens ("non-self"). Autoimmune disorders are prevented by the inactivation (tolerance) of lymphocytes with a sensitivity for "self" antigens during lymphocyte growth and differentiation. Additionally, commensal bacteria and dietary proteins shouldn't trigger an immune response. The gut is home to the majority of commensal bacteria. Thus, commensal microbial antigens and dietary antigens are in close proximity to the gut's mucosal immune system. The balanced development of the neonatal immune system, which is necessary to avoid infections, excessive activation (allergy), and misdirected reactions (autoimmunity) later in life, is shaped by these early contacts between the two parties. We'll talk about and contextualize the important participants in these interactions, which include particular bacteria and their metabolites, immune system cells, chemicals, and pathways [14-19].

Conclusions. Research on immunity and the microbiota is an exciting and quickly developing field. Understanding the molecular and functional interactions between various phyla of the microbiota and the immune system has advanced significantly in recent study. But there is a significant disconnect between research in the lab and effective therapies. We are at a standstill without additional clinical trials.

This immune-microbiota system is extremely intricate. We must determine precisely which chemical signals and molecular pathways are most important in order to decipher the code. Modern techniques like single-cell analysis and sophisticated gene sequencing may enable us to map these complex interactions with previously unheard-of resolution. Not to mention the prospect of individualized care—imagine medications tailored to each patient's particular microbiota.

Healthcare could be revolutionized if scientists can uncover this secret collaboration between our immune system and microorganisms. But cooperation is necessary to get there. As we advance, we need to address challenging issues about the precise ways in which our microscopic inhabitants affect various illnesses. By solving such puzzles, we can create precision therapies that improve health by adjusting this delicate equilibrium.

References:

1. Zeng J, He Z, Wang G, Ma Y, Zhang F. Interaction Between Microbiota and Immunity: Molecular Mechanisms, Biological Functions, Diseases, and New Therapeutic Opportunities. MedComm (2020). 2025 Jun 19;6(7):e70265. doi: 10.1002/mco2.70265.
2. Lu Y., Yuan X., Wang M., et al., "Gut Microbiota Influence Immunotherapy Responses: Mechanisms and Therapeutic Strategies," Journal of hematology & oncology 15, no. 1 (2022): 47.
3. Donald K. and Finlay B. B., "Early-life Interactions Between the Microbiota and Immune System: Impact on Immune System Development and Atopic Disease," Nature Reviews Immunology 23, no. 11 (2023): 735–748.
4. Anderson G., "A More Holistic Perspective of Alzheimer's Disease: Roles of Gut Microbiome, Adipocytes, HPA Axis, Melatonergic Pathway and Astrocyte Mitochondria in the Emergence of Autoimmunity," Front Biosci (Landmark Ed) 28, no. 12 (2023): 355.
5. Fogelson K. A., Dorrestein P. C., Zarrinpar A., et al., "The Gut Microbial Bile Acid Modulation and Its Relevance to Digestive Health and Diseases," Gastroenterology 164, no. 7 (2023): 1069–1085.
6. Nesci A., Carnuccio C., Ruggieri V., et al., "Gut Microbiota and Cardiovascular Disease: Evidence on the Metabolic and Inflammatory Background of a Complex Relationship," International Journal of Molecular Sciences 24, no. 10 (2023).
7. Zhao Y., Wang Y., Meng F., et al., "Altered Gut Microbiota as Potential Biomarkers for Autism Spectrum Disorder in Early Childhood," Neuroscience (2023): 523118–523131.
8. Hou K., Wu Z. X., Chen X. Y., et al., "Microbiota in Health and Diseases," Signal Transduct Target Ther 7, no. 1 (2022): 135.
9. Qiu P., Ishimoto T., Fu L., et al., "The Gut Microbiota in Inflammatory Bowel Disease," Frontiers in Cellular and Infection Microbiology (2022): 12733992.
10. Reynolds H. M. and Bettini M. L., "Early-life Microbiota-immune Homeostasis," Frontiers in immunology (2023): 141266876.
11. Mann E. R., Lam Y. K., and Uhlig H. H., "Short-chain Fatty Acids: Linking Diet, the Microbiome and Immunity," Nature Reviews Immunology 24, no. 8 (2024): 577–595.
12. Ignacio A., Czyz S., and McCoy K. D., "Early Life Microbiome Influences on Development of the Mucosal Innate Immune System," Seminars in Immunology (2024): 73101885.
13. Mruk-Mazurkiewicz H, Kulaszyńska M, Jakubczyk K, Janda-Milczarek K, Czarnecka W, Rębacz-Maron E, Zacha S, Sieńko J, Zeair S, Dalewski B, et al. Clinical Relevance of Gut Microbiota Alterations under the Influence of Selected Drugs—Updated Review. Biomedicines. 2023; 11(3):952. https://doi.org/10.3390/biomedicines11030952
14. Waide M.L., Schmidt N.W. The gut microbiome, immunity, and plasmodium severity. Curr. Opin. Microbiol. 2020;58:56–61. doi: 10.1016/j.mib.2020.08.006.
15. Santoni M., Miccini F., Battelli N. Gut microbiota, immunity and pain. Immunol. Lett. 2021;229:44–47. doi: 10.1016/j.imlet.2020.11.010.
16. Yao Y., Cai X., Fei W., Ye Y., Zhao M., Zheng C. The role of short-chain fatty acids in immunity, inflammation and metabolism. Crit. Rev. Food Sci. Nutr. 2020 doi: 10.1080/10408398.2020.1854675.

17. Tang MH, Ligthart I, Varga S, Lebeer S, van Overveld FJ, Rijkers GT. Mutual Interactions Between Microbiota and the Human Immune System During the First 1000 Days of Life. Biology. 2025; 14(3):299. https://doi.org/10.3390/biology14030299
18. Homeostatic Immunity and the Microbiotaю Belkaid, Yasmine et al. Immunity, Volume 46, Issue 4, 562 - 576
19. Louie T., Golan Y., Khanna S., et al., "VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial," Jama 329, no. 16 (2023): 1356–1366.
20. Carucci L., Nocerino R., Paparo L., et al., "Therapeutic Effects Elicited by the Probiotic Lacticaseibacillus Rhamnosus gg in Children With Atopic Dermatitis. The Results of the ProPAD Trial," Pediatric Allergy and Immunology 33, no. 8 (2022): e13836.
21. Elhossiny R. M., Elshahawy H. H., Mohamed H. M., et al., "Assessment of Probiotic Strain Lactobacillus Acidophilus LB Supplementation as Adjunctive Management of Attention-deficit Hyperactivity Disorder in Children and Adolescents: A Randomized Controlled Clinical Trial," BMC Psychiatry [Electronic Resource] 23, no. 1 (2023): 823.